Alkeus to detail Phase 3 gildeuretinol design for Stargardt disease at ASRS
The presentation pairs Phase 2 TEASE safety and efficacy data with the design of the enrolling Phase 3 NORTHSTAR trial, the study that will test whether gildeuretinol slows lesion growth against placebo.
Executive Summary
- Alkeus will use a retina specialists' meeting to lay out Phase 2 safety and efficacy findings for its Stargardt disease candidate alongside the design of the pivotal trial now underway, giving the field its first public look at how the company plans to test the drug at registrational scale.
- The pivotal trial is built to answer whether the drug slows the anatomic progression of a disease that currently has no approved way to change its course, in a population that spans children through adults.
- The registrational study has moved cleanly from initial registration to active recruitment on its original timeline, with its enrollment target and completion date unchanged and no protocol amendments recorded.
- No other program shares the drug's specific mechanism in this disease, and most late-stage rivals in the same small-molecule class or the emerging gene-therapy alternatives remain earlier in development or already resolved, leaving the field's central efficacy question unanswered by precedent.
The presentation
Alkeus Pharmaceuticals, Inc. said it will give an oral presentation titled "Oral Gildeuretinol for Slowing Stargardt Disease Progression: Safety and Efficacy Data From the Phase 2 TEASE Study and Phase 3 Study Design" during ASRS's Hereditary Retinal Disease and Genetics panel on July 18, 2026, in Montreal. Christine Kay, M.D., of Vitreo Retinal Associates will present the data, and a separate on-demand recording will cover baseline characteristics from the TEASE program, presented by Kenneth Fan, M.D.. Neither disclosure carries new posted trial results beyond what is already registered. AlkeusAlkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society ...Jul 9, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What Phase 3 will test
The trial in focus, NORTHSTAR (NCT07419334), is a randomized, placebo-controlled, double-masked, 24-month Phase 3 study enrolling approximately 230 participants aged 8 to 45 with a genetically confirmed diagnosis of Stargardt disease. Its primary endpoint is the annualized growth rate of retinal atrophic lesions measured by fundus autofluorescence, comparing gildeuretinol to placebo from months 6 to 24. The key secondary endpoint is change in low luminance visual acuity from baseline to month 24, a functional vision measure paired with the anatomic primary endpoint. Alkeus said the design builds on findings from more than 400 patients treated with gildeuretinol to date across its earlier studies. NCT07419334+1Study of ALK-001 on the Progression of Stargardt DiseaseNCT07419334Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society ...Jul 9, 2026
Trial status and stability
NORTHSTAR moved from Not yet recruiting to Recruiting on April 9, 2026, and the registry shows no change to its enrollment target of 230 or its primary completion date of October 1, 2029, since first posting on February 19, 2026. The trial's protocol has logged zero amendments and carries a Stable stability rating on registry-churn tracking. Alkeus separately disclosed dosing the first patient in the study in June 2026, consistent with a trial that started enrollment on schedule rather than one showing signs of delay. NCT07419334+1Study of ALK-001 on the Progression of Stargardt DiseaseNCT07419334Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society ...Jul 9, 2026
The competitive field
Gildeuretinol's mechanism, aimed at reducing vitamin A dimerization without altering the visual cycle, has no other Phase 3 program sharing that specific target in Stargardt disease. The nearest small-molecule precedents in the same disease, Belite Bio's tinlarebant (an RBP4-targeted retinol modulator, in Phase 2/3) and Kubota Vision's emixustat (an RPE65-targeted visual-cycle modulator, completed Phase 3), work through different targets within the broader retinol-pathway class. Gene-therapy programs from Ocugen, AAVantgarde, and Ray Therapeutics target the ABCA4 mutation directly but sit in Phase 1 or Phase 2. With no disease-modifying therapy approved in Stargardt disease, a result that shows a sustained reduction in lesion growth alongside preserved visual acuity through 24 months would be the finding that distinguishes gildeuretinol from that broader field.
Regulatory standing
Alkeus said gildeuretinol has received Breakthrough Therapy, Rare Pediatric Disease, Fast Track and Orphan Drug designations from the FDA for Stargardt disease, along with orphan medicinal product designation from the European Medicines Agency for ABCA4-related inherited retinal dystrophies. These designations reflect the disease's unmet need and enable closer FDA engagement; they do not indicate how the Phase 3 trial will read out. AlkeusAlkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society ...Jul 9, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.